Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A clinical-stage oncology company developing "MasterKey" therapies targeting oncogenic mutations. The lead asset is silevertinib (EGFR inhibitor) for non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The company outlicensed BDTX-4933 to Servier Pharmaceuticals in March 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| License Revenue | $0 | $70,000 |
| Total Operating Expenses | $11,259 | $15,470 |
| Net Income (Loss) | $(9,036) | $56,542 |
| Net Loss Per Share (Basic/Diluted) | $(0.16) | $1.00 / $0.98 |
| Cash, Cash Equivalents & Investments | $118,258 | $128,652 |
| Accumulated Deficit | $(473,776) | $(430,565) |
| Operating Cash Flow | $(10,232) | $53,410 |
Note: Q1 2025 included a $70 million upfront license payment from Servier, which significantly impacted revenue and net income for that period.
Material Changes vs. Prior Period
- Revenue: Decreased by $70.0 million due to the absence of the one-time Servier upfront payment recognized in Q1 2025. No license revenue was recorded in Q1 2026.
- Operating Expenses: Decreased by $4.2 million to $11.3 million.
- R&D: Decreased by $3.5 million to $7.0 million. This was driven by a $2.4 million reduction in silevertinib NSCLC costs and the cessation of BDTX-4933 development costs ($1.0 million) following the Servier license. These were partially offset by a $1.4 million increase in silevertinib GBM expenses due to the initiation of a Phase 2 trial.
- G&A: Decreased by $0.7 million to $4.3 million due to operational efficiencies.
- Liquidity: Cash and investments decreased by approximately $10.4 million quarter-over-quarter, primarily due to operating losses and changes in working capital, despite $19.5 million in proceeds from investment maturities.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- Silevertinib (NSCLC): Initial data from a Phase 2 frontline trial (43 patients) showed a 60% Objective Response Rate (ORR) and 86% CNS ORR. Updated results are expected at the ASCO Annual Meeting (May 29 – June 2, 2026).
- Silevertinib (GBM): Initiated a randomized Phase 2 trial in newly diagnosed EGFRvIII+ GBM patients; first patient dosed in May 2026.
- Liquidity Runway: Management believes existing cash, cash equivalents, and investments ($118.3 million as of March 31, 2026) are sufficient to fund operations into the second half of 2028.
- Capital Needs: The company expects to require substantial additional funding to support continued operations and growth. Future financing may include equity offerings, debt, or strategic collaborations.
- Risks:
- Dependence on the success of clinical trials for silevertinib.
- Uncertainty regarding the timing and receipt of milestone payments from Servier.
- Macroeconomic factors, including inflation, interest rates, and geopolitical conflicts.
- Potential dilution from future equity financings.
Investor Verification Checklist
- Clinical Data: Verify the upcoming ASCO presentation results for silevertinib in frontline NSCLC and the enrollment status of the new GBM Phase 2 trial.
- Liquidity Runway: Confirm the $118.3 million cash position and the validity of the "second half of 2028" funding estimate given current burn rates.
- Servier Milestones: Monitor the progress of BDTX-4933 under Servier's development to assess the probability of future milestone payments (up to $710 million).
- ATM Program: Review the status of the At-The-Market (ATM) offering program with Jefferies LLC, which has generated $25.0 million in gross proceeds to date.
- Expense Trends: Track R&D expenses to ensure the reduction in BDTX-4933 costs is not offset by accelerating costs in the silevertinib programs.